BioSpace News Archive

Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) today reported consolidated financial results for the year ended December 31, 2023.

Sunshine Biopharma Inc. today announced that it has filed its 2023 financial results on Form 10-K on Thursday March 28, 2024.

Addressing the growing need for complete ICP-MS and ICP-OES workflow automation in the lab Agilent Technologies Inc. announced the launch of the Advanced Dilution System, the ADS 2, a new automation workflow solution that will increase productivity, lower cost of ownership, and improve the overall efficiency within the laboratory.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that inaxaplin (VX-147) has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be compared to placebo, on top of standard of care.

Selux Diagnostics, Inc. announced they have received an additional $48 million to launch their next phase of commercialization of the Selux Next Generation Phenotyping System within the United States.

Viracta Therapeutics, Inc. today announced that topline results from Stage 1 of the NAVAL-1 trial of Nana-val.

Surrozen, Inc. announced that it has entered into securities purchase agreements with certain institutional and accredited investors to purchase shares of common stock, pre-funded warrants and accompanying warrants to purchase shares of common stock.

CMS Holdings Limited and Incyte are pleased to announce that on 31 March 2024, that the Group, through a wholly-owned dermatology medical aesthetic subsidiary of the Company, and Incyte entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib.

Teva Pharmaceutical Industries Ltd. and Launch Therapeutics, Inc., announced a clinical collaboration agreement to further accelerate the clinical research program of Teva’s ICS-SABA.

Spectral AI, Inc. today announced the appointment of Jeremiah A. Sparks as Chief Commercialization Officer. Jeremiah has more than 20 years of medical device marketing experience, including global marketing and business strategy.